Clinical Trial Update: Hydroxyurea With or Without Imatinib Mesylate in Treating Patients With Recurrent or Progressive Meningioma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating hydroxyurea with or without imatinib mesylate in patients with recurrent or progressive meningioma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningioma

Drugs mentioned

• HYDROXYUREA (Hydroxyurea)
• Imatinib mesylate (Imatinib)

Snippet

Sponsor: Istituto Scientifico H. San Raffaele | Conditions: Brain and Central Nervous System Tumors | Phase 2 | Status: UNKNOWN